Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin.
about
Acceptable changes in quality attributes of glycosylated biopharmaceuticalsCapillary electrophoresis and matrix-assisted laser desorption/ionization-time of flight-mass spectrometry for analysis of the novel erythropoiesis-stimulating protein (NESP).Evaluation of epoetin alpha (rHuEPO) and darbepoetin alpha (DARB) on human burst-colony formation (BFU-E) in culture.Every-other-week darbepoetin alfa in the correction and maintenance of haemoglobin levels in elderly patients with chronic kidney disease: post hoc subanalysis of data from two clinical trials.Glycosylation of therapeutic proteins: an effective strategy to optimize efficacyInterspecies scaling and prediction of human clearance: comparison of small- and macro-molecule drugsGlycosylation of the enhanced aromatic sequon is similarly stabilizing in three distinct reverse turn contextsNatural form of noncytolytic flexible human Fc as a long-acting carrier of agonistic ligand, erythropoietin.Highly sensitive capillary electrophoresis analysis of N-linked oligosaccharides in glycoproteins following fluorescence derivatization with rhodamine 110 and laser-induced fluorescence detection.Galactosyltransferase 4 is a major control point for glycan branching in N-linked glycosylation.Analytical platform for glycomic characterization of recombinant erythropoietin biotherapeutics and biosimilars by MS.Transforming growth factor beta receptor 2 (TGFBR2) changes sialylation in the microsatellite unstable (MSI) Colorectal cancer cell line HCT116Darbepoetin alpha reduces oxidative stress and chronic inflammation in atherosclerotic lesions of apo E deficient mice in experimental renal failure.Design of homogeneous, monopegylated erythropoietin analogs with preserved in vitro bioactivity.Darbepoetin alfa: a new approach to the treatment of chemotherapy-induced anaemia.Flexible dosing with Darbepoetin alfa for the treatment of chemotherapy-induced anemia.Epoetin beta for the treatment of chemotherapy-induced anemia: an update.A Systems Pharmacology Model of Erythropoiesis in Mice Induced by Small Molecule Inhibitor of Prolyl Hydroxylase Enzymes.The effects of potential neuroprotective agents on rat facial function recovery following facial nerve injury.Pharmacotherapy of chemotherapy-induced anaemia.The influence of artificially introduced N-glycosylation sites on the in vitro activity of Xenopus laevis erythropoietin.Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies.Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer.Effects of long-acting erythropoietin analog darbepoetin-α on adriamycin-induced chronic nephropathy.In silico design and analysis of a new hyperglycosylated analog of erythropoietin to improve drug efficacy.Population pharmacokinetics of darbepoetin alfa in healthy subjectsPopulation pharmacokinetics of darbepoetin alfa in haemodialysis and peritoneal dialysis patients after intravenous administrationThe use of darbepoetin alfa for the treatment of chemotherapy-induced anaemia.A retrospective assessment of pre-treatment variables on the response to darbepoetin alfa after renal transplantation.Anaemia in cancer patients: pathophysiology, incidence and treatment.QUANTITY: An Isobaric Tag for Quantitative Glycomics.Modifications of therapeutic proteins: challenges and prospects.N-glycosylation of enhanced aromatic sequons to increase glycoprotein stabilityCurrent and future options for the treatment of chemotherapy-induced anaemia.Correction of anaemia through the use of darbepoetin alfa improves chemotherapeutic outcome in a murine model of Lewis lung carcinoma.Clinical outcomes associated with conversion from epoetin alfa to darbepoetin alfa in hospitalized hemodialysis patients.Darbepoetin alfa: an effective treatment with flexible and simplified dosing for anemia in patients with cancer.Darbepoietin-alfa has comparable erythropoietic stimulatory effects to recombinant erythropoietin whilst preserving the bone marrow microenvironmentTargeted erythropoietin selectively stimulates red blood cell expansion in vivo.Allometry of factor VIII and informed scaling of next-generation therapeutic proteins.
P2860
Q28235143-64B13A71-9972-47C6-B093-F5A2C517D68BQ33212718-8F050E77-133A-40B4-9B2C-9C6A1454CFF7Q33239436-F273C132-999A-4D39-97A3-7740FB3E5139Q33494136-995D9DCE-EA11-4CC8-A906-6719FD1FFE6AQ33586660-C290C1A1-0FE5-4C38-B599-57F532224D1AQ34011214-8A0FFCA6-4077-48E4-A597-989295B1D23EQ34028044-99257B4B-8449-460E-BF94-73523083FB9FQ34034670-244916BC-F525-46E6-8F25-CE63301E5C65Q34105021-5A9354C6-57E4-47C5-90EF-BEBDEC8AC5F6Q34589283-D99E9981-5C8F-4DC8-964F-2868C7B6FC6DQ34593205-66F9A020-D15E-410D-A7B5-04817191E404Q34611732-0B88FE97-9F6E-4ECE-8897-51F874D09494Q35106161-6BE46068-0768-4F3A-99D7-D3A0D80342E8Q35126977-937F88E5-8111-4A0C-BC4D-116C65A2F31AQ35144050-ECAE8908-B837-475B-805D-C35C4E857F79Q35166812-B8B57F64-4836-41F6-9D9B-F52A53DD3850Q35168681-53AF8BD9-A850-4494-AAC8-E0D104273CF5Q35179547-30E0BAE0-9B04-409E-817E-D0EF95DF53B9Q35556725-537DA188-2477-4DD4-BDAA-3A956FE33E43Q35593977-3456CFBD-6F45-485F-9B75-877A1DC85F9DQ35610754-0114FFAC-D115-4D7E-AC97-76F74C417ECDQ35684362-BA30A827-9F8A-4297-AA58-E557CE63836CQ35858979-B2D733EC-1F1D-408E-BBA8-00F91CF19D9FQ35867619-CC7EE0EF-E1B5-46FB-9A75-DCEE03BAF7D3Q35997019-F14F02AB-4EDF-4540-BD0A-D7A2096D968FQ36024876-FC03FF1D-F8A6-4A7F-888E-C5F1669A3A89Q36025060-25D2A7D5-9349-4618-BD22-4243852D6E55Q36082066-EDC70F79-C0C6-465B-94D3-E9AF41801E05Q36183304-69F4D53D-A0D9-43FE-A6EC-C077037525F4Q36310891-8706CADC-2C6A-404F-B7E0-FBCDA61B2954Q36329430-F78F94AC-8FE0-4FE4-985C-17912678DCDFQ36495973-258EE4C0-8466-4A60-B0E3-63107BE90542Q36515262-FC5FD3D1-0473-4607-A3D2-34C22A8B54DBQ36568736-85F315B2-12E4-480E-BB5F-423E6BF05882Q36615053-2E378E56-EE9B-47DB-89BB-608E71754D50Q36684706-2C0B329C-5696-4AA0-B182-D428126E3FA5Q36742415-E91F2933-00C1-428C-9503-31927A37DBB4Q36805820-2A21D340-F3B6-4C43-BFFC-BD7E43F6055FQ36905103-3752749E-5285-401F-A83A-1F2F2C66D936Q36912731-D773B48F-BBEA-4121-B0D1-E549EB2A6C3C
P2860
Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Darbepoetin alfa has a longer ...... ombinant human erythropoietin.
@en
type
label
Darbepoetin alfa has a longer ...... ombinant human erythropoietin.
@en
prefLabel
Darbepoetin alfa has a longer ...... ombinant human erythropoietin.
@en
P2093
P1476
Darbepoetin alfa has a longer ...... ombinant human erythropoietin.
@en
P2093
Erik Dwyer
Jeffrey K Browne
Joan C Egrie
Michele A Lykos
P304
P356
10.1016/S0301-472X(03)00006-7
P577
2003-04-01T00:00:00Z